ATE311185T1 - Triazole als oxytocin-antagonisten - Google Patents
Triazole als oxytocin-antagonistenInfo
- Publication number
- ATE311185T1 ATE311185T1 AT02799064T AT02799064T ATE311185T1 AT E311185 T1 ATE311185 T1 AT E311185T1 AT 02799064 T AT02799064 T AT 02799064T AT 02799064 T AT02799064 T AT 02799064T AT E311185 T1 ATE311185 T1 AT E311185T1
- Authority
- AT
- Austria
- Prior art keywords
- triazole derivatives
- vasopressin
- present
- oxytocin
- triazoles
- Prior art date
Links
- 150000003852 triazoles Chemical class 0.000 title abstract 2
- 239000003336 oxytocin antagonist Substances 0.000 title 1
- 229940121361 oxytocin antagonists Drugs 0.000 title 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 abstract 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 abstract 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract 2
- 108010004977 Vasopressins Proteins 0.000 abstract 2
- 102000002852 Vasopressins Human genes 0.000 abstract 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 abstract 2
- 229960001723 oxytocin Drugs 0.000 abstract 2
- 229960003726 vasopressin Drugs 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 206010030043 Ocular hypertension Diseases 0.000 abstract 1
- 101800000989 Oxytocin Proteins 0.000 abstract 1
- 102000004279 Oxytocin receptors Human genes 0.000 abstract 1
- 108090000876 Oxytocin receptors Proteins 0.000 abstract 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 abstract 1
- 208000005107 Premature Birth Diseases 0.000 abstract 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 abstract 1
- 206010036590 Premature baby Diseases 0.000 abstract 1
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract 1
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 208000037849 arterial hypertension Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01000778 | 2001-12-20 | ||
| PCT/EP2002/014594 WO2003053437A1 (en) | 2001-12-20 | 2002-12-19 | Triazoles as oxytocin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE311185T1 true ATE311185T1 (de) | 2005-12-15 |
Family
ID=8176114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02799064T ATE311185T1 (de) | 2001-12-20 | 2002-12-19 | Triazole als oxytocin-antagonisten |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7468385B2 (de) |
| EP (1) | EP1458381B1 (de) |
| JP (1) | JP4511184B2 (de) |
| AT (1) | ATE311185T1 (de) |
| AU (1) | AU2002364291B2 (de) |
| CA (1) | CA2469042A1 (de) |
| DE (1) | DE60207755T2 (de) |
| DK (1) | DK1458381T3 (de) |
| ES (1) | ES2249636T3 (de) |
| IL (1) | IL162615A0 (de) |
| SI (1) | SI1458381T1 (de) |
| WO (1) | WO2003053437A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75145C2 (en) * | 2001-06-18 | 2006-03-15 | Applied Research Systems | Pyrrolidine oxadiazole and thiadiazole derivatives, pharmaceutical composition based thereon, a method for producing thereof (variants) |
| ATE311185T1 (de) | 2001-12-20 | 2005-12-15 | Applied Research Systems | Triazole als oxytocin-antagonisten |
| JP2007505888A (ja) * | 2003-09-22 | 2007-03-15 | ファイザー インコーポレイテッド | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
| US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
| CA2545767A1 (en) * | 2003-12-11 | 2005-06-30 | Galderma Research & Development, S.N.C. | Novel compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| WO2005082866A2 (en) * | 2004-02-20 | 2005-09-09 | Pfizer Limited | Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists |
| GB0412874D0 (en) * | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Novel pharmaceuticals |
| GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
| EP1863484A1 (de) * | 2005-03-21 | 2007-12-12 | Pfizer Limited | Substituierte triazolderivate als oxytocinantagonisten |
| US20100222365A1 (en) * | 2005-08-10 | 2010-09-02 | Pfizer Inc | Substituted triazole deriviatives as oxytocin antagonists |
| US8226949B2 (en) * | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
| DE102010040924A1 (de) * | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE570978A (de) * | 1957-09-09 | |||
| EP0048555B1 (de) | 1980-08-27 | 1985-12-04 | Glaxo Group Limited | Amino-1,2,4-triazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
| EP0409332A3 (en) * | 1989-07-19 | 1991-08-07 | Merck & Co. Inc. | Substituted triazoles as angiotensin ii antagonists |
| FR2665441B1 (fr) | 1990-07-31 | 1992-12-04 | Sanofi Sa | Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant. |
| FR2679903B1 (fr) | 1991-08-02 | 1993-12-03 | Elf Sanofi | Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant. |
| US5187179A (en) | 1991-03-22 | 1993-02-16 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole |
| WO1996022775A1 (en) | 1995-01-24 | 1996-08-01 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5756497A (en) | 1996-03-01 | 1998-05-26 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| CA2305802C (en) * | 1997-10-17 | 2008-11-18 | Yamanouchi Pharmaceutical Co., Ltd. | Amide derivatives or salts thereof |
| FR2789077A1 (fr) | 1999-02-02 | 2000-08-04 | Synthelabo | Derives de perazole, leur preparation et leur application en therapeutique |
| AU2000223275A1 (en) * | 2000-02-08 | 2001-08-20 | Yamanouchi Pharmaceutical Co..Ltd. | Novel triazole derivatives |
| ATE311185T1 (de) | 2001-12-20 | 2005-12-15 | Applied Research Systems | Triazole als oxytocin-antagonisten |
-
2002
- 2002-12-19 AT AT02799064T patent/ATE311185T1/de not_active IP Right Cessation
- 2002-12-19 US US10/498,356 patent/US7468385B2/en not_active Expired - Fee Related
- 2002-12-19 CA CA002469042A patent/CA2469042A1/en not_active Abandoned
- 2002-12-19 DK DK02799064T patent/DK1458381T3/da active
- 2002-12-19 JP JP2003554194A patent/JP4511184B2/ja not_active Expired - Fee Related
- 2002-12-19 WO PCT/EP2002/014594 patent/WO2003053437A1/en active IP Right Grant
- 2002-12-19 ES ES02799064T patent/ES2249636T3/es not_active Expired - Lifetime
- 2002-12-19 EP EP02799064A patent/EP1458381B1/de not_active Expired - Lifetime
- 2002-12-19 DE DE60207755T patent/DE60207755T2/de not_active Expired - Lifetime
- 2002-12-19 SI SI200230246T patent/SI1458381T1/sl unknown
- 2002-12-19 IL IL16261502A patent/IL162615A0/xx unknown
- 2002-12-19 AU AU2002364291A patent/AU2002364291B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2469042A1 (en) | 2003-07-03 |
| US20050187275A1 (en) | 2005-08-25 |
| DK1458381T3 (da) | 2006-03-20 |
| WO2003053437A1 (en) | 2003-07-03 |
| IL162615A0 (en) | 2005-11-20 |
| AU2002364291A1 (en) | 2003-07-09 |
| AU2002364291B2 (en) | 2007-08-02 |
| EP1458381B1 (de) | 2005-11-30 |
| SI1458381T1 (sl) | 2006-04-30 |
| JP4511184B2 (ja) | 2010-07-28 |
| JP2005517662A (ja) | 2005-06-16 |
| US7468385B2 (en) | 2008-12-23 |
| DE60207755T2 (de) | 2006-07-27 |
| DE60207755D1 (de) | 2006-01-05 |
| EP1458381A1 (de) | 2004-09-22 |
| ES2249636T3 (es) | 2006-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1401902A (en) | Pharmaceutically active sulfanilide derivatives | |
| ATE311185T1 (de) | Triazole als oxytocin-antagonisten | |
| JP2023162279A (ja) | ミトコンドリア標的化ペプチド | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| NO20064811L (no) | 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase | |
| NO20064151L (no) | Nye forbindelser | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| MA27305A1 (fr) | Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales | |
| JPWO2007083689A1 (ja) | プラスミノーゲンアクチベーターインヒビター−１阻害剤 | |
| DE69921994T2 (de) | Heterozyklische verbindungen mit faktor xa hemmender wirkung | |
| TW200410963A (en) | Heterocyclic derivatives | |
| BRPI1011439B1 (pt) | composlção de alta penetração, composição farmacêutica, sistemas de aplicação terapêutico transdérmico e uso de referida composição | |
| SE0104331D0 (sv) | Novel compounds | |
| NO20032261L (no) | Medisinske preparater | |
| RO111270B1 (ro) | Derivati de 4-alchilimidazol | |
| MD523G2 (ro) | Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin | |
| ATE246684T1 (de) | Substituierte 1,4-dihydroindeno(1,2-c)pyrazole als inhibitoren von tyrosinkinase | |
| RS99503A (en) | Pyrrolidine oxadiazole- and thiadiazole derivatives | |
| ATE384714T1 (de) | Pyrazolderivate | |
| CA2548790A1 (en) | Medicinal compositions and combinations | |
| CN119486724A (zh) | 用于治疗顽固性高血压或心力衰竭合并肺动脉高压的rxfp1调节剂 | |
| CN119325376A (zh) | Rxfp1调节剂和sglt2抑制剂的组合 | |
| EP0483403A1 (de) | Aminsäurederivate mit renininhibierender Aktivität, Verfahren zu deren Herstellung und pharmazeutische Zubereitungen die sie enthalten | |
| WO2015188060A1 (en) | FLUOROSULFONYL sEH INHIBITORS | |
| US9115082B2 (en) | Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1458381 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |